Using rodents to model schizophrenia and substance use comorbidity

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 5, 2013, Pages 896-910

  Ng, Enoch ^a,b   McGirr, Alexander ^d   Wong, Albert H C ^b,c   Roder, John C ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Comorbidity; COMT (catechol O methyl transferase); DISC1 (disrupted in schizophrenia 1); Dopamine; Dysbindin; Neonatal ventral hippocampal lesion; Neuregulin; Neurexin; Prenatal immune activation; Schizophrenia; Self administration; Substance use disorder

Indexed keywords

AMPHETAMINE; BUNGAROTOXIN RECEPTOR; CANNABIS; CATECHOL METHYLTRANSFERASE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DYSBINDIN; METHAMPHETAMINE; NEU DIFFERENTIATION FACTOR; NEUREXIN; NEUROLEPTIC AGENT; NICOTINE; NICOTINIC AGENT; TC 5619; TC 7020; UNCLASSIFIED DRUG;

BRAIN DAMAGE; COGNITION; COMORBIDITY; DISEASE MODEL; DRUG EFFECT; EARLY LIFE STRESS; GENE MUTATION; GENE SILENCING; GENETIC MODEL; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HIPPOCAMPUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SMOKING; SUBSTANCE ABUSE; TOBACCO DEPENDENCE;

ANIMALS; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); DISEASE MODELS, ANIMAL; ENVIRONMENT; HUMANS; RODENTIA; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 84877053077     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.03.025     Document Type: Review

References (161)

1. Abazyan B., Nomura J., Kannan G., Ishizuka K., Tamashiro K.L., Nucifora F., Pogorelov V., Ladenheim B., Yang C., Krasnova I.N., Cadet J.L., Pardo C., Mori S., Kamiya A., Vogel M.W., Sawa A., Ross C.A., Pletnikov M.V. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol. Psychiatry 2010, 68:1172-1181.
2. Amitai N., Markou A. Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration. Psychopharmacology (Berl) 2009, 202:275-286.
3. Andreasson S., Engstr A., Allebeck P., Rydberg U.L.F. Cannabis and schizophrenia. A longitudinalstudy of Swedish conscripts. Lancet 1976, 1483-1486.
4. Arguello P.A., Gogos J.A. Modeling madness in mice: one piece at a time. Neuron 2006, 52:179-196.
5. Arguello P.A., Gogos J.A. Genetic and cognitive windows into circuit mechanisms of psychiatric disease. Trends Neurosci. 2012, 35:3-13.
6. Balleine B.W., O'Doherty J.P. Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 2010, 35:48-69.
7. Beaulieu J.-M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu. Rev. Pharmacool. Toxicol. 2009, 49:327-347.
8. Becker A., Grecksch G., Bernstein H.G., Höllt V., Bogerts B. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology (Berl) 1999, 144:333-338.
9. Behan A.T., Hryniewiecka M., O'Tuathaigh C.M.P., Kinsella A., Cannon M., Karayiorgou M., Gogos J.A.Waddington J.L., Cotter D.R. Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 2012, 37:1773-1783.
10. Belin D., Mar A.C., Dalley J.W., Robbins T.W., Everitt B.J. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008, 320:1352-1355.
11. Berg S.A., Chambers R.A. Accentuated behavioral sensitization to nicotine in the neonatal ventral hippocampal lesion model of schizophrenia. Neuropharmacology 2008, 54:1201-1207.
12. Bhardwaj S.K., Baharnoori M., Sharif-Askari B., Kamath A., Williams S., Srivastava L.K. Behavioral characterization of dysbindin-1 deficient sandy mice. Behav. Brain Res. 2009, 197:435-441.
13. Bierut L.J., Madden P.A.F., Breslau N., Johnson E.O., Hatsukami D., Pomerleau O.F., Swan G.E., Rutter J., Bertelsen S., Fox L., Fugman D., Goate A.M., Hinrichs A.L., Konvicka K., Martin N.G., Montgomery G.W., Saccone N.L., Saccone S.F., Wang J.C., Chase G.A., Rice J.P., Ballinger D.G. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum. Mol. Genet. 2007, 16:24-35.
14. Blednov Y.a., Benavidez J.M., Geil C., Perra S., Morikawa H., Harris R.a. Activation of inflammatory signaling by lipopolysaccharide produces a prolonged increase of voluntary alcohol intake in mice. Brain Behav. Immun. 2011, 25(Suppl. 1):S92-S105.
15. Boksa P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav. Immun. 2010, 24:881-897.
16. Boucher A.A., Arnold J.C., Duffy L., Schofield P.R., Micheau J., Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 2007, 192:325-336.
17. Boucher A.A., Hunt G.E., Karl T., Micheau J., McGregor I.S., Arnold J.C. Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 2007, 149:861-870.
18. Boucher A.A., Hunt G.E., Micheau J., Huang X., McGregor I.S., Karl T., Arnold J.C. The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int. J. Neuropsychopharmacol. 2011, 14:631-643.
19. Bouvrais-Veret C., Weiss S., Andrieux A., Schweitzer A., McIntosh J.M., Job D., Giros B., Martres M.-P. Sustained increase of alpha7 nicotinic receptors and choline-induced improvement of learning deficit in STOP knock-out mice. Neuropharmacology 2007, 52:1691-1700.
20. Brady A.M., McCallum S.E., Glick S.D., O'Donnell P. Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia. Psychopharmacology (Berl) 2008, 200:205-215.
21. Brandon N.J., Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat. Rev. Neurosci. 2011, 12:707-722.
22. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 2010, 167:261-280.
23. Brunzell D.H., McIntosh J.M. Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia. Neuropsychopharmacology 2012, 37:1134-1143.
24. Bushnell P.J., Oshiro W.M., Padnos B.K. Detection of visual signals by rats: effects of chlordiazepoxide and cholinergic and adrenergic drugs on sustained attention. Psychopharmacology (Berl) 1997, 134:230-241.
25. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
26. Chambers R.A., Jones R.M., Brown S., Taylor J.R. Natural reward-related learning in rats with neonatal ventral hippocampal lesions and prior cocaine exposure. Psychopharmacology (Berl) 2005, 179:470-478.
27. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 2001, 50:71-83.
28. Chambers R.A., Moore J., McEvoy J.P., Levin E.D. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 1996, 15:587-594.
29. Chambers R.A., Self D.W. Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia. Neuropsychopharmacology 2002, 27:889-905.
30. Chambers R.A., Sentir A.M., Conroy S.K., Truitt W.A., Shekhar A. Cortical-striatal integration of cocaine history and prefrontal dysfunction in animal modeling of dual diagnosis. Biol. Psychiatry 2010, 67:788-792.
31. Chambers R.A., Sentir A.M., Engleman E.A. Ventral and dorsal striatal dopamine efflux and behavior in rats with simple vs. co-morbid histories of cocaine sensitization and neonatal ventral hippocampal lesions. Psychopharmacology (Berl) 2010, 212:73-83.
32. Chambers R.A., Taylor J.R. Animal modeling dual diagnosis schizophrenia: sensitization to cocaine in rats with neonatal ventral hippocampal lesions. Biol. Psychiatry 2004, 56:308-316.
33. Choy K.H.C., de Visser Y.P., van den Buuse M. The effect of 'two hit' neonatal and young-adult stress on dopaminergic modulation of prepulse inhibition and dopamine receptor density. Br. J. Pharmacol. 2009, 156:388-396.
34. Chung K., Wallace J., Kim S.-Y., Kalyanasundaram S., Andalman A.S., Davidson T.J., Mirzabekov J.J., et al. Structural and molecular interrogation of intact biological systems. Nature 2013, 10.1038/nature12107.
35. Cirulli E.T., Goldstein D.B. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat. Rev. Genet. 2010, 11:415-425.
36. Clapcote S.J., Lipina T.V., Millar J.K., Mackie S., Christie S., Ogawa F., Lerch J.P., Trimble K., Uchiyama M., Sakuraba Y., Kaneda H., Shiroishi T., Houslay M.D., Henkelman R.M., Sled J.G., Gondo Y., Porteous D.J., Roder J.C. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 2007, 54:387-402.
37. Conroy S.K., Rodd Z., Chambers R.A. Ethanol sensitization in a neurodevelopmental lesion model of schizophrenia in rats. Pharmacol. Biochem. Behav. 2007, 86:386-394.
38. Consortium C.D.G.o.t.P.G Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013, 6736:1-9.
39. Counotte D.S., Goriounova N.a.Li K.W., Loos M., van der Schors R.C., Schetters D., Schoffelmeer A.N.M., Smit A.B., Mansvelder H.D., Pattij T., Spijker S. Lasting synaptic changes underlie attention deficits caused by nicotine exposure during adolescence. Nat. Neurosci. 2011, 14:417-419.
40. Counotte D.S., Smit A.B., Spijker S. The Yin and Yang of nicotine: harmful during development, beneficial in adult patient populations. Front. Pharmacol. 2012, 3:180.
41. Counotte D.S., Spijker S., Van de Burgwal L.H., Hogenboom F., Schoffelmeer A.N.M., De Vries T.J., Smit A.B., Pattij T. Long-lasting cognitive deficits resulting from adolescent nicotine exposure in rats. Neuropsychopharmacology 2009, 34:299-306.
42. Court J.A., Martin-Ruiz C., Graham A., Perry E. Nicotinic receptors in human brain: topography and pathology. J. Chem. Neuroanat. 2000, 20:281-298.
43. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 2006, 26:365-384.
44. Cui K., Ashdown H., Luheshi G.N., Boksa P. Effects of prenatal immune activation on hippocampal neurogenesis in the rat. Schizophr. Res. 2009, 113:288-297.
45. D'Souza M.S., Markou A. Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 2012, 62:1564-1573.
46. De Hert M., Wampers M., Jendricko T., Franic T., Vidovic D., De Vriendt N., Sweers K., Peuskens J., van Winkel R. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. Schizophr. Res. 2011, 126:270-276.
47. de Leon J., Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 2005, 76:135-157.
48. De Luca V., Wong A.H.C., Muller D.J., Wong G.W.H., Tyndale R.F., Kennedy J.L. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 2004, 29:1522-1526.
49. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 1999, 35(Suppl.):S93-S100.
50. Enoch M.-A. The role of early life stress as a predictor for alcohol and drug dependence. Psychopharmacology (Berl) 2011, 214:17-31.
51. Ersche K.D., Turton A.J., Pradhan S., Bullmore E.T., Robbins T.W. Drug addiction endophenotypes: impulsive versus sensation-seeking personality traits. Biol. Psychiatry 2010, 68:770-773.
52. Etherton M.R., Blaiss C.A., Powell C.M., Su T.C. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17998-18003.
53. Everitt B.J., Robbins T.W. From the ventral to the dorsal striatum: devolving views of their roles in drug addiction. Neurosci. Biobehav. Rev. 2013, 1-10.
54. Featherstone R.E., Burton C.L., Coppa-Hopman R., Rizos Z., Sinyard J., Kapur S., Fletcher P.J. Gestational treatment with methylazoxymethanol (MAM) that disrupts hippocampal-dependent memory does not alter behavioural response to cocaine. Pharmacol. Biochem. Behav. 2009, 93:382-390.
55. Featherstone R.E., Kapur S., Fletcher P.J. The amphetamine-induced sensitized state as a model of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1556-1571.
56. Fernando A.B.P., Robbins T.W. Animal models of neuropsychiatric disorders. Annu. Rev. Clin. Psychol. 2011, 7:39-61.
57. Floresco S.B., Todd C.L., Grace A.A. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J. Neurosci. 2001, 21:4915-4922.
58. Floresco S.B., West A.R., Ash B., Moore H., Grace A.A. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat. Neurosci. 2003, 6:968-973.
59. Fowles D.C. Schizophrenia: diathesis-stress revisited. Annu. Rev. Psychol. 1992, 43:303-336.
60. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:587-592.
61. Freedman R., Hall M., Adler L.E., Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry 1995, 38:22-33.
62. Gainetdinov R.R. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999, 283:397-401.
63. Gainetdinov R.R., Jones S.R., Fumagalli F., Wightman R.M., Caron M.G. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res. 1998, 26:148-153.
64. Gauthier J., Siddiqui T.J., Huashan P., Yokomaku D., Hamdan F.F., Champagne N., Lapointe M., Spiegelman D., Noreau A., Lafrenière R.G., Fathalli F., Joober R., Krebs M.-O., DeLisi L.E., Mottron L., Fombonne E., Michaud J.L., Drapeau P., Carbonetto S., Craig A.M., Rouleau G.A. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum. Genet. 2011, 130:563-573.
65. Gill M., Donohoe G., Corvin A. What have the genomics ever done for the psychoses?. Psychol. Med. 2010, 40:529-540.
66. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
67. Grace A.A., Bunney B.S. The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci. 1984, 4:2877-2890.
68. Grecksch G., Bernstein H.G., Becker a., Höllt V., Bogerts B. Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology 1999, 20:525-532.
69. Green A.I., Drake R.E., Brunette M.F., Noordsy D.L. Schizophrenia and co-occurring substance use disorder. Am. J. Psychiatry 2007, 164:402-408.
70. Guan Z.Z., Zhang X., Blennow K., Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 1999, 10:1779-1782.
71. Haque F.N., Lipina T.V., Roder J.C., Wong A.H.C. Social defeat interacts with Disc1 mutations in the mouse to affect behavior. Behav. Brain Res. 2012, 233:337-344.
72. Hauser T.A., Kucinski A., Jordan K.G., Gatto G.J., Wersinger S.R., Hesse R.A., Stachowiak E.K., Stachowiak M.K., Papke R.L., Lippiello P.M., Bencherif M. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol. 2009, 78:803-812.
73. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr. Bull. 2009, 35:549-562.
74. Hradetzky E., Sanderson T.M., Tsang T.M., Sherwood J.L., Fitzjohn S.M., Lakics V., Malik N., Schoeffmann S., O'Neill M.J., Cheng T.M., Harris L.W., Rahmoune H., Guest P.C., Sher E., Collingridge G.L., Holmes E., Tricklebank M.D., Bahn S. The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus. Neuropsychopharmacology 2012, 37:364-377.
75. Hunt G.E., Bergen J., Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr. Res. 2002, 54:253-264.
76. Insel T., Cuthbert B., Garvey M., Heinssen R., Pine D.S., Quinn K., Sanislow C., Wang P. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 2010, 167:748-751.
77. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
78. Jacobsen L.K., Slotkin T.A., Mencl W.E., Frost S.J., Pugh K.R. Gender-specific effects of prenatal and adolescent exposure to tobacco smoke on auditory and visual attention. Neuropsychopharmacology 2007, 32:2453-2464.
79. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:4029-4034.
80. Karl T., Burne T.H., Van den Buuse M., Chesworth R. Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?. Behav. Brain Res. 2011, 223:336-341.
81. Karl T., Duffy L., Scimone A., Harvey R.P., Schofield P.R. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav. 2007, 6:677-687.
82. Khandaker G.M., Zimbron J., Lewis G., Jones P.B. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol. Med. 2012, 1-19.
83. Khantzian E.J. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv. Rev. Psychiatry 1997, 4:231-244.
84. Kishimoto M., Ujike H., Motohashi Y., Tanaka Y., Okahisa Y., Kotaka T., Harano M., Inada T., Yamada M., Komiyama T., Hori T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biol. Psychiatry 2008, 63:191-196.
85. Klejbor I., Myers J.M., Hausknecht K., Corso T.D., Gambino A.S., Morys J., Maher P.a.Hard R., Richards J., Stachowiak E.K., Stachowiak M.K. Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice. J. Neurochem. 2006, 97:1243-1258.
86. Koob G.F., Le Moal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2008, 363:3113-3123.
87. Kucinski A., Syposs C., Wersinger S., Bencherif M., Stachowiak M.K., Stachowiak E.K. α7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia. Schizophr. Res. 2012, 136:82-87.
88. Le Pen G., Moreau J.-L. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 2002, 27:1-11.
89. Lederle L., Weber S., Wright T., Feyder M., Brigman J.L., Crombag H.S., Saksida L.M., Bussey T.J., Holmes A. Reward-related behavioral paradigms for addiction research in the mouse: performance of common inbred strains. PLoS ONE 2011, 6:e15536.
90. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles-Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 1996, 22:431-445.
91. Leonard S., Breese C., Adams C., Benhammou K., Gault J., Stevens K., Lee M., Adler L., Olincy A., Ross R., Freedman R. Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur. J. Neurosci. 2000, 393:237-242.
92. Levin E.D., Bradley A., Addy N., Sigurani N. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 2002, 109:757-765.
93. Levin E.D., McClernon F.J., Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 2006, 184:523-539.
94. Ling Z., Gayle D.A., Ma S.Y., Lipton J.W., Tong C.W., Hong J.-s., Carvey P.M. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov. Disord. 2002, 17:116-124.
95. Lipina T.V., Kaidanovich-Beilin O., Patel S., Wang M., Clapcote S.J., Liu F., Woodgett J.R., Roder J.C. Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse 2011, 65:234-248.
96. Lipina T.V., Niwa M., Jaaro-Peled H., Fletcher P.J., Seeman P., Sawa A., Roder J.C. Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes Brain Behav. 2010, 9:777-789.
97. Lipska B.K., Aultman J.M., Verma A., Weinberger D.R., Moghaddam B. Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology 2002, 27:47-54.
98. Lipska B.K., Jaskiw G.E., Weinberger D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 1993, 9:67-75.
99. Liu X., Lee J.G., Yee S.K., Bresee C.J., Poland R.E., Pechnick R.N. Endotoxin exposure in utero increases ethanol consumption in adult male offspring. Neuroreport 2004, 15:203-206.
100. Lodge D.J., Grace A.A. Amphetamine activation of hippocampal drive of mesolimbic dopamine neurons: a mechanism of behavioral sensitization. J. Neurosci. 2008, 28:7876-7882.
101. Lodge D.J., Grace A.A. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav. Brain Res. 2009, 204:306-312.
102. Lodge D.J., Grace A.A. Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia. Int. J. Neuropsychopharmacol. 2012, 15:69-76.
103. Long L.E., Chesworth R., Arnold J.C., Karl T. A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology (Berl) 2010, 211:277-289.
104. Long L.E., Chesworth R., Huang X.-F., McGregor I.S., Arnold J.C., Karl T. Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. Int. J. Neuropsychopharmacol. 2012, 1-13.
105. Lynch W.J., Nicholson K.L., Dance M.E., Morgan R.W., Foley P.L. Animal models of substance abuse and addiction: implications for science, animal welfare, and society. Comp. Med. 2010, 60:177-188.
106. Makinodan M., Tatsumi K., Manabe T., Yamauchi T., Makinodan E., Matsuyoshi H., Shimoda S., Noriyama Y., Kishimoto T., Wanaka A. Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring. J. Neurosci. Res. 2008, 86:2190-2200.
107. Malone D.T., Hill M.N., Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br. J. Pharmacol. 2010, 160:511-522.
108. Marutle A., Zhang X., Court J., Piggott M., Johnson M., Perry R., Perry E., Nordberg A. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J. Chem. Neuroanat. 2001, 22:115-126.
109. McCormick C.M. An animal model of social instability stress in adolescence and risk for drugs of abuse. Physiol. Behav. 2010, 99:194-203.
110. Mexal S., Berger R., Logel J., Ross R.G., Freedman R., Leonard S. Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J. Mol. Neurosci. 2010, 40:185-195.
111. Meyer U., Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog. Neurobiol. 2010, 90:285-326.
112. Meyer U., Nyffeler M., Engler A., Urwyler A., Schedlowski M., Knuesel I., Yee B.K., Feldon J. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J. Neurosci. 2006, 26:4752-4762.
113. Moore H., Jentsch J.D., Ghajarnia M., Geyer M.A., Grace A.A. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol. Psychiatry 2006, 60:253-264.
114. Mueser K.T., Drake R.E., Wallach M.A. Dual diagnosis: a review of etiological theories. Addict. Behav. 1998, 23:717-734.
115. Murotani T., Ishizuka T., Hattori S., Hashimoto R., Matsuzaki S., Yamatodani A. High dopamine turnover in the brains of Sandy mice. Neurosci. Lett. 2007, 421:47-51.
116. Murray J.E., Belin D., Everitt B.J. Double dissociation of the dorsomedial and dorsolateral striatal control over the acquisition and performance of cocaine seeking. Neuropsychopharmacology 2012, 37:2456-2466.
117. Nagai T., Kitahara Y., Shiraki A., Hikita T., Taya S., Kaibuchi K., Yamada K. Neuroscience Letters Dysfunction of dopamine release in the prefrontal cortex of dysbindin deficient sandy mice: an in vivo microdialysis study. Neurosci. Lett. 2010, 470:134-138.
118. Niwa M., Kamiya A., Murai R., Kubo K.-i.Gruber A.J., Tomita K., Lu L., Tomisato S., Jaaro-Peled H., Seshadri S., Hiyama H., Huang B., Kohda K., Noda Y., O'Donnell P., Nakajima K., Sawa A., Nabeshima T. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron 2010, 65:480-489.
119. Nussbaum J., Xu Q., Payne T.J., Ma J.Z., Huang W., Gelernter J., Li M.D. Significant association of the neurexin-1 gene (NRXN1) with nicotine dependence in European- and African-American smokers. Hum. Mol. Genet. 2008, 17:1569-1577.
120. O'Brien C.P., Gardner E.L. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol. Ther. 2005, 108:18-58.
121. O'Connor, E.C., Stephens, D.N., Crombag, H.S., 2010. Modeling appetitive Pavlovian-instrumental interactions in mice. Curr. Protoc. Neurosci. Chapter 8, Unit 8.25.
122. O'Tuathaigh C.M.P., Clarke G., Walsh J., Desbonnet L., Petit E., O'Leary C., Tighe O., Clarke N., Karayiorgou M., Gogos J.a., Dinan T.G., Cryan J.F., Waddington J.L. Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int. J. Neuropsychopharmacol. 2011, 1-12.
123. O'Tuathaigh C.M.P., Hryniewiecka M., Behan A., Tighe O., Coughlan C., Desbonnet L., Cannon M., Karayiorgou M., Gogos J.a.Cotter D.R., Waddington J.L. Chronic adolescent exposure to (-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 2010, 35:2262-2273.
124. Overton P.G., Clark D. Burst firing in midbrain dopaminergic neurons. Brain Res. 1997, 25:312-334.
125. Owen M.J., Craddock N., O'Donovan M.C. Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch. Gen. Psychiatry 2010, 67:667-673.
126. Paintlia M.K., Paintlia A.S., Contreras M.a., Singh I., Singh A.K. Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: attenuation by N-acetyl cysteine. Exp. Neurol. 2008, 210:560-576.
127. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., Chen J. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J. Neurosci. 2008, 28:8709-8723.
128. Pletnikov M.V., Ayhan Y., Nikolskaia O., Xu Y., Ovanesov M.V., Huang H., Mori S., Moran T.H., Ross C.A. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol. Psychiatry 2008, 13:173-186. 115.
129. Pogorelov V.M., Nomura J., Kim J., Kannan G., Ayhan Y., Yang C., Taniguchi Y., Abazyan B., Valentine H., Krasnova I.N., Kamiya A., Cadet J.L., Wong D.F., Pletnikov M.V. Mutant DISC1 affects methamphetamine-induced sensitization and conditioned place preference: a comorbidity model. Neuropharmacology 2012, 62:1242-1251.
130. Potvin S., Briand C., Prouteau A., Bouchard R.-H., Lipp O., Lalonde P., Nicole L., Lesage A., Stip E. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn. 2005, 59:38-42.
131. Potvin S., Sepehry A.A., Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol. Med. 2006, 36:431-440.
132. Pritchard J.K., Cox N.J. The allelic architecture of human disease genes: common disease-common variant. .or not?. Hum. Mol. Genet. 2002, 11:2417-2423.
133. Quinn J.J., Pittenger C., Lee A.S., Pierson J.L., Taylor J.R. Striatum-dependent habits are insensitive to both increases and decreases in reinforcer value in mice. Eur. J. Neurosci. 2013, 1-10.
134. Ralph R.J., Paulus M.P., Fumagalli F., Caron M.G., Geyer M.A. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J. Neurosci. 2001, 21:305-313.
135. Reichelt A.C., Rodgers R.J., Clapcote S.J. The role of neurexins in schizophrenia and autistic spectrum disorder. Neuropharmacology 2012, 62:1519-1526.
136. Reijmers L.G., Perkins B.L., Matsuo N., Mayford M. Localization of a stable neural correlate of associative memory. Science 2007, 317:1230-1233.
137. Rezvani A.H., Kholdebarin E., Dawson E., Levin E.D. Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. Int. J. Neuropsychopharmacol. 2008, 11:63-70.
138. Richtand N.M., Ahlbrand R., Horn P.S., Chambers B., Davis J., Benoit S. Effects of prenatal immune activation and peri-adolescent stress on amphetamine-induced conditioned place preference in the rat. Psychopharmacology (Berl) 2012, 313-324.
139. Rodriguez-Murillo L., Gogos J.a., Karayiorgou M. The genetic architecture of schizophrenia: new mutations and emerging paradigms. Annu. Rev. Med. 2012, 63:63-80.
140. Rossi, M.A., Yin, H.H., 2012. Methods for studying habitual behavior in mice. Curr. Protoc. Neurosci. Chapter 8, Unit 8.29.
141. Roumier A., Pascual O., Béchade C., Wakselman S., Poncer J.-C., Réal E., Triller A., Bessis A. Prenatal activation of microglia induces delayed impairment of glutamatergic synaptic function. PLoS ONE 2008, 3:e2595.
142. Russell W., Burch R. The Principles of Humane Experimental Technique 1959, Universities Federation for Animal Welfare, Wheathampstead, UK.
143. Saccone N.L., Schwantes-An T.-H., Wang J.C., Grucza R.A., Breslau N., Hatsukami D., Johnson E.O., Rice J.P., Goate a.M., Bierut L.J. Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans. Genes Brain Behav. 2010, 9:741-750.
144. Salamone J.D., Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron 2012, 76:470-485.
145. Schmidt L.M., Hesse M., Lykke J.r. The impact of substance use disorders on the course of schizophrenia--a 15-year follow-up study: dual diagnosis over 15 years. Schizophr. Res. 2011, 130:228-233.
146. Schultz W. Dopamine signals for reward value and risk: basic and recent data. Behav. Brain Funct. 2010, 6:24.
147. St Clair D., Blackwood D., Muir W., Carothers A., Walker M., Spowart G., Gosden C., Evans H.J. Association within a family of a balanced autosomal translocation with major mental illness. Lancet 1990, 336:13-16.
148. Stephens S.H., Logel J., Barton A., Franks A., Schultz J., Short M., Dickenson J., James B., Fingerlin T.E., Wagner B., Hodgkinson C., Graw S., Ross R.G., Freedman R., Leonard S. Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophr. Res. 2009, 109:102-112.
149. Sullivan P.F., Daly M.J., O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat. Rev. Genet. 2012, 13:537-551.
150. Swerdlow N.R., Light G.a.Breier M.R., Shoemaker J.M., Saint Marie R.L., Neary A.C., Geyer M.a.Stevens K.E., Powell S.B. Sensory and sensorimotor gating deficits after neonatal ventral hippocampal lesions in rats. Dev. Neurosci. 2012, 34:240-249.
151. Talbot K. The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research. Prog. Brain Res. 2009, 179:87-94.
152. Tang J., LeGros R.P., Louneva N., Yeh L., Cohen J.W., Hahn C.-G., Blake D.J., Arnold S.E., Talbot K. Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Hum. Mol. Genet. 2009, 18:3851-3863.
153. Thoma P., Wiebel B., Daum I. Response inhibition and cognitive flexibility in schizophrenia with and without comorbid substance use disorder. Schizophr. Res. 2007, 92:168-180.
154. Tien L.-T., Cai Z., Rhodes P.G., Fan L.-W. Neonatal exposure to lipopolysaccharide enhances methamphetamine-induced reinstated behavioral sensitization in adult rats. Behav. Brain Res. 2011, 224:166-173.
155. Tseng K.Y., Chambers R.A., Lipska B.K. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav. Brain Res. 2009, 204:295-305.
156. Valenti O., Lodge D.J., Grace A.A. Aversive stimuli alter ventral tegmental area dopamine neuron activity via a common action in the ventral hippocampus. J. Neurosci. 2011, 31:4280-4289.
157. Walsh T., McClellan J.M., McCarthy S.E., Addington A.M., Pierce S.B., Cooper G.M., Nord A.S., Kusenda M., Malhotra D., Bhandari A., Stray S.M., Rippey C.F., Roccanova P., Makarov V., Lakshmi B., Findling R.L., Sikich L., Stromberg T., Merriman B., Gogtay N., Butler P., Eckstrand K., Noory L., Gochman P., Long R., Chen Z., Davis S., Baker C., Eichler E.E., Meltzer P.S., Nelson S.F., Singleton A.B., Lee M.K., Rapoport J.L., King M.-C., Sebat J. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008, 320:539-543.
158. Weiss S., Nosten-Bertrand M., McIntosh J.M., Giros B., Martres M.-P. Nicotine improves cognitive deficits of dopamine transporter knockout mice without long-term tolerance. Neuropsychopharmacology 2007, 32:2465-2478.
159. Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am. J. Addict. 2006, 15:345-355.
160. Zager A., Mennecier G., Palermo-Neto J. Maternal immune activation in late gestation enhances locomotor response to acute but not chronic amphetamine treatment in male mice offspring: role of the D1 receptor. Behav. Brain Res. 2012, 232:30-36.
161. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. Self reported cannabis use as a risk factor for historical cohort study. BMJ 2002, 325:1-5.